BiondVax Awarded $1 Million Universal Flu Vaccine Grant from Israeli Office of the Chief Scientist
BiondVax Awarded $1 Million Universal Flu Vaccine Grant from Israeli Office of the Chief Scientist
Israeli biopharmaceutical company BiondVax Pharmaceuticals Ltd. has been awarded a one-year $1 million grant from the Israeli Office of the Chief Scientist, a division of the Israeli Ministry of Trade and Industry, to advance its clinical development program for the universal influenza vaccine.
This new grant is the third consecutive grant that BiondVax has received from the Israeli Office of the Chief Scientist, following previous grants of $580,000 and $720,000 received in April 2009 and January 2008, respectively.
The research at BiondVax focuses on a universal influenza vaccine that incorporates a proprietary combination of multiple conserved epitopes from influenza virus proteins to activate both humoral and cellular immunity, to provide protection against both seasonal and pandemic flu strains. BiondVax recently concluded the second of two Phase 1–2 clinical trials and the company’s universal flu vaccine was shown to be safe and well tolerated, and to effectively activate both arms (humoral and cellular) of the human immune system, stimulating immune responses against both Influenza Type A and Influenza Type B strains, in both of these Phase 1–2 trials.
Previous coverage Phase 1-2 Completed for Universal Influenza VaccinePandemic Response: Progress and Challenges
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
